资产负债表（Taro Pharmaceutical Industries Ltd）
| 2023年三季报 | 2023年中报 | 2023年一季报 | 2022年年报 | 2022年中报 | 2022年一季报 | |
|---|---|---|---|---|---|---|
| 截止日期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 |
| 报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
| 报表年结日 | 0331 | 0331 | 0331 | 0331 | 0331 | 0331 |
| 原始币种 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 |
| 上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
| 流动资产： | ||||||
| 现金及现金等价物(元) | 382,409,000.00 | 269,011,000.00 | 124,165,000.00 | 154,495,000.00 | 175,191,000.00 | 225,801,000.00 |
| 受限制存款及现金流动(元) | 56,480,000.00 | 119,980,000.00 | 119,980,000.00 | 119,980,000.00 | 95,630,000.00 | 22,586,000.00 |
| 应收账款及票据(元) | 191,232,000.00 | 181,064,000.00 | 226,873,000.00 | 202,260,000.00 | 248,495,000.00 | 325,188,000.00 |
| 预付款项及其他应收款流动(元) | 39,140,000.00 | 46,254,000.00 | 56,555,000.00 | 57,210,000.00 | 53,097,000.00 | - |
| 存货(元) | 214,816,000.00 | 208,188,000.00 | 204,592,000.00 | 226,669,000.00 | 215,524,000.00 | 216,833,000.00 |
| 短期投资(元) | 463,327,000.00 | 518,058,000.00 | 562,008,000.00 | 575,814,000.00 | 568,671,000.00 | 557,859,000.00 |
| 流动资产合计(元) | 1,347,404,000.00 | 1,342,555,000.00 | 1,294,173,000.00 | 1,336,428,000.00 | 1,356,608,000.00 | 1,348,267,000.00 |
| 非流动资产： | ||||||
| 物业、厂房及设备(元) | 218,385,000.00 | 189,893,000.00 | 189,590,000.00 | 190,139,000.00 | 191,489,000.00 | 194,805,000.00 |
| 商誉(元) | 17,231,000.00 | 17,231,000.00 | 17,231,000.00 | 17,231,000.00 | 12,718,000.00 | 12,718,000.00 |
| 递延所得税资产非流动(元) | 97,300,000.00 | 100,807,000.00 | 101,386,000.00 | 103,672,000.00 | 124,167,000.00 | 123,573,000.00 |
| 长期投资(元) | 403,544,000.00 | 388,370,000.00 | 451,174,000.00 | 404,896,000.00 | 357,586,000.00 | 374,968,000.00 |
| 非流动资产其他项目(元) | 79,315,000.00 | 80,617,000.00 | 81,495,000.00 | 83,147,000.00 | 64,711,000.00 | 65,661,000.00 |
| 非流动资产合计(元) | 815,775,000.00 | 776,918,000.00 | 840,876,000.00 | 799,085,000.00 | 750,671,000.00 | 771,725,000.00 |
| 总资产(元) | 2,163,179,000.00 | 2,119,473,000.00 | 2,135,049,000.00 | 2,135,513,000.00 | 2,107,279,000.00 | 2,119,992,000.00 |
| 流动负债： | ||||||
| 应付账款及票据(元) | 51,183,000.00 | 43,059,000.00 | 59,368,000.00 | 68,484,000.00 | 61,356,000.00 | 73,923,000.00 |
| 应付税项流动(元) | - | - | - | 33,011,000.00 | - | - |
| 应付薪酬和福利(元) | - | - | - | 23,055,000.00 | - | - |
| 其他应付款及应计费用(元) | - | - | - | 23,953,000.00 | - | - |
| 流动负债其他项目(元) | 322,876,000.00 | 318,429,000.00 | 325,638,000.00 | 237,045,000.00 | 313,495,000.00 | 300,529,000.00 |
| 流动负债合计(元) | 374,059,000.00 | 361,488,000.00 | 385,006,000.00 | 385,548,000.00 | 374,851,000.00 | 374,452,000.00 |
| 非流动负债： | ||||||
| 递延所得税负债非流动(元) | 10,027,000.00 | 10,429,000.00 | 11,511,000.00 | - | 26,148,000.00 | 31,826,000.00 |
| 非流动负债其他项目(元) | - | - | - | 19,106,000.00 | - | - |
| 非流动负债合计(元) | 10,027,000.00 | 10,429,000.00 | 11,511,000.00 | 19,106,000.00 | 26,148,000.00 | 31,826,000.00 |
| 总负债(元) | 384,086,000.00 | 371,917,000.00 | 396,517,000.00 | 404,654,000.00 | 400,999,000.00 | 406,278,000.00 |
| 股东权益： | ||||||
| 普通股(元) | - | - | - | 679,000.00 | - | - |
| 库存股(元) | - | - | - | -771,406,000.00 | - | - |
| 股本溢价(元) | - | - | - | 262,445,000.00 | - | - |
| 留存收益(元) | - | - | - | 2,414,136,000.00 | - | - |
| 累计其他全面收益(元) | - | - | - | -174,996,000.00 | - | - |
| 归属于母公司股东权益其他项目(元) | - | - | - | 1,000.00 | - | - |
| 归属于母公司股东权益(元) | 1,779,093,000.00 | 1,747,556,000.00 | 1,738,532,000.00 | 1,730,859,000.00 | 1,706,280,000.00 | 1,713,714,000.00 |
| 股东权益合计(元) | 1,779,093,000.00 | 1,747,556,000.00 | 1,738,532,000.00 | 1,730,859,000.00 | 1,706,280,000.00 | 1,713,714,000.00 |
| 负债及股东权益合计(元) | 2,163,179,000.00 | 2,119,473,000.00 | 2,135,049,000.00 | 2,135,513,000.00 | 2,107,279,000.00 | 2,119,992,000.00 |
| 公告日期 | 2024-01-26 | 2023-10-27 | 2023-07-27 | 2023-06-29 | 2022-11-09 | 2022-07-28 |
| 会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 |
| 审计意见 | ||||||
| 核数师 |